InvestorsHub Logo
Followers 22
Posts 3667
Boards Moderated 0
Alias Born 07/20/2006

Re: None

Sunday, 05/26/2024 8:11:48 AM

Sunday, May 26, 2024 8:11:48 AM

Post# of 3019
FWIW - Good news for a potential buyer?

Enanta Pharmaceuticals sees highest patent filings and grants during February in Q1 2024

Excerpts:
Enanta Pharmaceuticals saw the highest growth of 199% in patent filings in February and 499% in grants in January in Q1 2024. Compared to Q4 2023, Q1 2024 saw an increase in patent filings by 24% and grants by 499%.

Patents related to rare diseases and Covid-19 lead Enanta Pharmaceuticals's portfolio
Enanta Pharmaceuticals has the highest number of patents in rare diseases followed by, Covid-19 and climate change. For rare diseases, nearly 50% of patents were filed and 38% of patents were granted in Q1 2024.

Respiratory syncytial virus (rsv) infections related patents lead Enanta Pharmaceuticals portfolio followed by cardiovascular disease, and fatty liver disease
Enanta Pharmaceuticals has highest number of patents in respiratory syncytial virus (rsv) infections followed by cardiovascular disease, fatty liver disease, non alcoholic fatty liver disease (nafld), and non-alcoholic steatohepatitis (nash).

Read more:
https://www.pharmaceutical-technology.com/data-insights/enanta-pharmaceuticals-patent-activity/?cf-view
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News